Signed in as:
filler@godaddy.com
Signed in as:
filler@godaddy.com
Revised prescribing alert January 2024
https://www.gov.uk/government/news/mhra-introduces-new-restrictions-for-fluoroquinolone-antibiotics
European Medicines Agency’s (EMA) Fluoroquinolone Press Release 2019:
European Medicines Agency’s (EMA) Fluoroquinolone Public Hearing 2018:
Summary -
Main points raised -
• Symptoms were life-changing and wide ranging
• Patients were not given information about risks
• Healthcare professionals were generally unaware of the range and severity of possible symptoms,
with the exception of Achilles tendon disorders
13 patient testimonies before the EMA starting at minute 14:15
https://www.youtube.com/watch?v=1vao8o5NGUc
___________________________________________________________________________________________________
Pharmacovigilance Risk Assessment Committee (PRAC) Assessment Report 2018:
The following mechanisms may be supportive of a causal relationship between (fluoro) quinolones and tendon disorders:
Tendon disorders
Neurotoxicity
Neuropathies
Phototoxicity
Vasculitis
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has strengthened its guidance on a group of antibiotics known as fluoroquinolones. These include common drugs like ciprofloxacin, levofloxacin, and moxifloxacin. The move comes after new evidence confirmed that these medications can cause serious, long-lasting, and sometimes permanent side effects in some patients.
Your support will help fund our work
On your Zelle account, copy and paste our email address to transfer your donation to our foundation: fq100@protonmail.com